BioMarin Pharmaceuticals BMRN Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's total current liabilities?
- BioMarin Pharmaceuticals (BMRN) reported total current liabilities of $793.15M in Q1 2026.
- How has BioMarin Pharmaceuticals's total current liabilities changed year-over-year?
- BioMarin Pharmaceuticals's total current liabilities increased by 26.3% year-over-year, from $628.21M to $793.15M.
- What is the long-term trend for BioMarin Pharmaceuticals's total current liabilities?
- Over 5 years (2020 to 2025), BioMarin Pharmaceuticals's total current liabilities has grown at a 9.0% compound annual growth rate (CAGR), from $492.55M to $759.03M.
- What does total current liabilities mean?
- All debts and obligations that the company must pay within the next twelve months.
- How do you interpret total current liabilities?
- A rising trend relative to current assets may signal potential liquidity pressure or a need for short-term financing.
- How does total current liabilities compare across companies?
- Standard liquidity metric; essential for comparing short-term solvency across the pharmaceutical sector.